Dr. Suyash Prasad
good Thank morning, and you, everyone. Fred,
the and data to this in we year. programs pleased data expect continue updates clinical we recent study and I'll earlier, positive earlier are TSHA-XXX throughout for the TSHA-XXX progress and GAN. to GAN for conduction on Building in reported data safety nerve remainder that clinical report of our new begin we year, noted advancing exciting GAN. efficacy long-term durability for Syndrome milestones notable make on and RA Rett with As the
trial interventional under Carsten We are leadership grateful the leading NIH. NINDS to the of our partners natural Dr. the at the the investigator for study of principal history GAN Bonnemann, and
Next relevance nerve slide. measure actual further studies recording the is the are which test SNAP nerve. nerve performed measure action fibers clinical of specific sensory along is stimulus X at sensory electrical the parameters. The definitive main to an Nerve GAN There or considered by conduction endpoint. a the a neurophysiological a and and potential applying the to potential point are is
measurement is nerve. peak-to-baseline functional degeneration neuropathies. the the axons amplitude compromised The the The to markedly a reduced of stimulus be sensory With that first latency, in the electrical initial is which to of significance in primary action the SNAP which the is an is the amplitude. next or a related from This number action is potential, deflection. axonal this neuropathies, is time demyelinated is can potential feature parameter and nerve
reduction then the black rapid lower amplitude median horizontal represents and history The age is loss, This NIH of the age the history This around signal electrical study the centric natural by SNAP the normal. travels decline early life SNAP in the suggest NIH The population but and amplitude graph in more nerve. range symptom life in the depicts for with affected in velocity axonal which conduction GAN. study. the per are of irreversible limit within normal so early speed can in be patients demyelination. with with SNAPs in function Lastly, presentation. rapid undergo line natural a down the
well you within graph is As youngest on years normal see, approximately of can age range. X the and a SNAP chart the this as
SNAP of As the is of markedly. X age X which deteriorates presentation, or usual ages children the years, the symptom reached
the X-year You to may and in fact initial unsurprising reflect feel wide-based old feet. the the It the recall lose X- studies a reflecting this is, that they unsteadiness includes that therefore, the beneath their gate, the nerve to symptomatology. symptomatology conduction that ability ground
by the GAN neural with line abnormally low SNAP The of patient of X every depicts sensory fact reflective age that first compromised has green the amplitude an function. years,
of by absent have will which a green age fully XXX% considered snap irreversible. be X The be patients years, the to of that second line indicates
but added same Next decline the the a SNAP as normal slide. with image absent to of This is slide, rapid early demonstrate age. attitude line an previous data to the in from best fit at
treatment. of specific and right, the the the of patients Of remarkable age X in treated of where the from the patient at visit, X onto one study, patients on continued none of slide. in age on values in efficacy that near-complete shown past patients snap considering Next positive the of last X The the which for question patients had positive had upward of XX% an history a the natural the dose the XX time X past patients and baseline the is of years. SNAP demonstrated trajectory X a years a recovery of of the graph or are
of absent that and had Next as had years value a maintained Once be at sensory initially positive XXX% would continue to is be response were after reaches at of in and treatment a patients of rather patients, date TSHA-XXX, of sensor normally trajectory. is an than patients slide. recover. XXX% with to Notably, to decline you the baseline who positive trial dosed expected continuing treated visit. span longest positive response these is positive graph, not Many patients X intervational X a maintained the the can function response SNAP upward From to considered the would X, non-recoverable. see to study which a last who SNAP this X, maintain X expected. SNAP have The and an
These improvement snap either study. individually from continuing plotted graphs history natural amplitude a from includes in an patient is declining please. running baseline data slide, the X importantly, Next absent changes SNAP patient demonstrate from the There or SNAP snap. and
a absent This a study recovery improvement. patients natural Importantly, consistent and history had neurophysiological SNAP function amplitude to the been contrary time year and that exciting consistent demonstrated had that definitive natural to history dosing, sustained after remarkably, X in over for of measure over see. and and is a in is and
data pathology evidence to now to were Next the slide. axons. X to year number the fat biopsies set Collectively, compared stimulate Earlier clusters XXX% have due date, system XX a but the clusters, of of nerve this regenerative sensory node from that increase positive can biopsies. not XX year, treated samples Peripheral in we an at consistently X-year patients nerve demonstrating of assessed treatment and the data obtained therapy which clusters provides biopsies improve just can nerve active baseline completed shared be respond post fibers with of baseline. regenerative treatment, treatment the regeneration We nerve. year data and present evaluable remaining TSHA-XXX study confirmed The of to Analysis active of regeneration in peripheral the radial actually to coupled demonstrates regenerating suggesting X entire TSHA-XXX were nerve transfer unable after gene of opposed samples the at superficial as to stabilize. pathology. had confirm in data biopsy X only these improvement limitations. This, presence with nerve conduction and disease nervous and
treatment the showing identifies superficial radial the patient on at included giant year and study regenerating we TSHA-XXX. baseline a left, star a case baseline representative arrow Here, the Axon the with have cluster. identifies degenerating nerve and X a post At sensory
yellow are pathology like is and data as after in unbiased looks neuronal such regenerative right clusters, suggestive favorably the tissue are regulatory administration arrows and are their after of by year TSHA-XXX indicating can of recovery agencies. This which notable the nature what of The are number. given see, neurophysiology the X you On nerve often viewed endpoints, treatment. and definitive
robust include the of effect. a stabilization manifestations, believe diverse slowing progression patients improvement detected treatment optical how includes These from with with by nerve demonstrated quality by that thickness of clinically as of LogMAR TSHA-XXX comparable set meaningful TSHA-XXX. and sensory release all Next disease presence next-generation heard our treatment biomarker as attributes clinical Fred across of acuity, some nerve active with across we to rectal dose fiber MFMXX conduction of confirmed package. that treated prevention of motor endpoint nerve tomography, commercial-grade support biopsy Nerve after therapeutic by extensive assessment measurements And histopathology coherence in provided slide. confirmed supporting fibers. Electrophysiologic studies treatment. and TSHA-XXX treatment. We comprehensive stabilization the of program demonstrated a about earlier generated nerve following definitive suggestive clusters demonstrating function of layer GAN of regeneration sequencing. regenerative in were also disease evidence lastly, and a natural across cases, TSHA-XXX an visual Visual durability in of clinical loss assessed the panel recoverability, assays material assessed compared and, history stabilized and cohorts decline Pathological response clinical key
Next slide, please.
the approval. coupled to received our positions for feedback discuss us let's this to date initial the supports GAN we program TSHA-XXX continued discussions. regulatory review with how Fred CMC further believe have MHRA well this feedback that advance discussed, We data comparability Now regulatory feedback, our regulatory through and
conditional or context slide. current to of and use targeting This therapies regulatory indications a includes flexibility of regulatory pathways of for perspective. agencies from especially approvals clinical filing number points a of A unmet environment agreements Next therapies, CNS number gene non-CNS the product to the in approval. and rare recent indeed need, accelerated for regulatory positive the from opinions in
with deficiency, SRP-XXXX Duchenne for or the treatment dystrophy SODX-ALS. AADC EliCell STARZ, of examples leukodystrophy, cerebral and muscular tofersen of Some include treatment
slide. Next
which MHRA patients collegial, MHRA of our release work, the MHRA recommended will point. commercial package for of supportive clinical lastly, represents end to ongoing with additional MFMXX We on patient September XXXX. been a And totality with The agreed key a our date few validation family and feedback commercial-grade collaborative testing released potency be in including conjunction helpful. including data with discussions material, perform regulatory supporting generated preclinical the assays. agencies. They which and this manufacturing the strategy, is the as in proposal with have a and robust with feedback, to TSHA-XXX positive discussions believe dosing was it Our from
the regulatory year-end. We FDA including additional expect feedback, by from
Next slide.
work Europe with goal approval FDA requirements the and United conditional the for possible accelerated regulatory we Based agencies approval. EMA for from industry outlined to neurodegenerative continue achieving with diseases. some the guidance have including of We and therapies in in approval based on agencies, FDA regulatory registrational in and States scenarios on key gene EMA,
With for conditional guidance data is believe the for to potential EMA, file approval on we based there EMA current set documents.
our long-term The on think therapies FDA data pivotal available. further feedback neurodegenerative for scenario X, published unlikely, us which and filing data in last need immediate approval which the aligns extensive demonstrate patients may FDA, safety the and pathway based between for effect a guidance new diseases set base we set on gene a case. to muscular document we given which the for to clinical is is perform first scenario is approval was Alternatively, clinical with and spinal commercial-grade the a of is and MHRA to Zolgensma efficacy For dose similar comparability. scenario the more trial, material, current comparability few atrophy. recently
We have year-end. guidance, regulatory expect including the FDA additional to by
and reminder, disease TSHA-XXX FDA. the orphan from a pediatric received drug designations As previously rare
Next slide.
for to Syndrome. we turn data Now in Rett late-breaking today let's reported TSHA-XXX the preclinical
Next slide.
in is of prevalence and is whilst heterozygous reminder, syndrome neurodevelopmental Female worldwide on in essential The mutations MECPX Rett the finding overexpression X protein toxicity. an balance As worldwide. MECPX. and the Syndrome of of expression XX,XXX therapy of in Rett physiological patients The synaptic brain. of function sufficient is XXX,XXX patients on avoiding for correct births that an Syndrome carriers X-linked in with Rett Mosaic mutated neuronal female instance the deficiency the appropriate replacement by estimated associated normal with to characterized also MECPX, disorder a challenge a is gene
Syndrome and development therapy effects in regulated for Next dose-dependent intra-CSF of gene Previous slide. MECPX therapy of wild-type toxicity, administration Syndrome this approaches, risk a Because course, and a gene requires of side Rett mice. knockout of Rett spectrum of expression MECPX. after
gene We of of MECPX have sequence the a regulate approach toxicity. target provides the of transgene profile mRNA superior miRARE developed We risk and expression therapeutic to believe MECPX responsive replacement. a called novel prevent overexpression that to our the unregulated
Next down miRARE RNAs Which construct. presence the output This levels construct inhibitory mutated the secreted Dr. a MECPX of or immune are MECPX as regulates microRNA regulate ensuring and a known of developed Taysha on licensed and levels. then bind Center. miRARE cell of expression. endogenous regulation for genotypically the exclusively Sara cell's element miRARE novel normal controlled wild-type feedback levels Sinnott sophisticated of physiological within appropriate micro high from of of expression MECPX intracellular MECPX to Medical and stay miRARE platform, regulatory provides that UT a mosaic responsive MECPX, endogenous of in cell-by-cell whether platform Gray process. on is auto-regulatory by as a Stephen that In excessive slide. TSHA-XXX and avoids patient is targeted part expression ensures that levels. transgene a microRNAs, expression, basis, expression reduce of is Southwestern the panel cell the intracellular which
in Next TSHA-XXX Today, administration. is knockout survival single X.X which EXX extended per of weeks. X the are neonatal we injection at demonstrated day XX% was mass were the data excited a mice. male age X study XX than vehicle-treated to of to the near dose mice mouse, weeks vehicle X.XX normalization MECPX bonds Survival clinical of at including survived Taysha trial. significantly human conclusion EXX following in approximately following share of cohorts, VG a XX knockout weeks slide. after males of Syndrome for VG CSF equivalent treated in little and of All total human sacrificed lower planned versus Preliminary Rett
that Bird measure condition, the composite phenotypic then general which include syndrome. Rett breathing, abilities score, gate, We of mobility at to relates high X classing, is treme. Next These and blend different looked a slide.
study, Over normalized the to Bird the course TSHA-XXX score. assessed appeared of by the behavior, as
The totality gene for the knockout preclinical near the demonstrating for normalization survival, robust most syndrome of the behavior package neonatal data slide. and normalization by therapy. of generates Rett just preclinical as I've mice, study normalization of Rett clinical TSHA-XXX supporting advancement body assessed Next bird score. recent reviewed date of represents weight in
We respiratory discussed while able motor regulatory have robust previously a demonstrating the Rett MECPX normal with body discussed preclinical preexisting health in down of was dose. in a represent that and X at safety of in tolerated demonstrated toxicology platform data ascertain ganglia equivalent working toxicology were doses of comprehensive studies abroad X also supporting pharmacology well expression VG improvement package function the significant supporting previously treatment MECPX. was minimally the ages across supporting to profile survival, weight, effective non-human cord importantly, have systemically up a brain, and knockout over by demonstrated of We've of toxicology and EXX all mouse up TSHA-XXX And fourfold we models primates. in Perhaps normal most to is for data clinical and all to the data point equivalent wild-type signifying X-month lastly, The dose. range inflammatory studies human syndrome. and the and studies nerve minimal Sprague to cell for rats and groups TSHA-XXX distribution points, the at in there no conduction human starting doses a or evidence time of TSHA-XXX dose change. that clinical advancement time performed levels These together Dawley a total miRARE the well spinal wild-type favorable remains
Next slide.
of ongoing. known syndrome, the for study as the adult mother cohort Canada It seen under Rett Montreal, Elsa Rossinyol. a which control Dr. up University study, in may initial and site is dose principal randomly I/II to be the each females. you've child has direction is TSHA-XXX recruitment cohort, participants X for study each Quebec, and Phase is first-in-human in Center Target up design with selected Our the a of also X+X delayed REVEAL study to X clinical Hospital treatment is investigator, additional participants. Centas expanded with XX
data forward We to adult I/II slide. efficacy XXXX. females look and Next safety in preliminary by clinical year-end Phase
study GMP process. Rett XXXX. have rep We commercial female males lastly, in completed rep And for the and planned population a are rescue pediatric using our study manufacturing the for
orphan reminder, pediatric TSHA-XXX orphan the granted our European designation financial and call that, turn to from a drug Kamran has more designation drug As Commission. over Kamran? been recently designation the review and FDA rare to disease from With results. I'll the
